Semaglutide effects: the upsides, the downsides, and who has a reason to be careful.

Start here

This page is the honest version of "what does Semaglutide actually do to you." Two layers sit here, kept strictly apart. The first is what people who use it describe — useful for context, but it is anecdote, not proof. The most common thing they report is that hunger and "food noise" go quiet, cravings fade, and weight comes off; the most common complaint is nausea and other stomach upset, especially in the first weeks. The second layer is the cited safety record from controlled trials and drug-safety monitoring: the stomach effects are real and well documented, a handful of specific groups have a clear reason for caution, and weight tends to come back if the drug is stopped. No doses appear on this page, and nothing here is medical advice — it is a plain-English reading of the published record and the community's reports.

What people report

These are effects described by the research-use and patient community — anecdotal, not clinical evidence, and not verified by controlled trials. No doses are attached to any of them.

Benefits people describe most often

• Quieter "food noise" and faster fullness (frequently reported). The single most common theme is that the constant background chatter about food goes quiet, often within the first week or two. People say they feel full faster, eat a third to a half of their old portions, and stop circling back to the next meal. Many call it the most life-changing part.
• Cravings drop (frequently reported). Sweet-tooth and sugar cravings fade or vanish, and fried, greasy, high-fat foods stop appealing — sometimes turning slightly off-putting. Several people say they drift toward fruit, vegetables and lighter meals on their own.
• Weight loss (frequently reported). The large majority report losing weight, often steady and substantial over months, with the pace slowing after the early stretch. Many tie it directly to eating much less rather than to exercise.
• Better blood-sugar numbers (commonly reported, among people using it for type 2 diabetes). A common theme is markedly improved blood-sugar and A1C readings, with steadier daytime energy.
• Less interest in alcohol (occasionally reported). A recurring side observation is that the urge to drink fades along with food cravings — discussed widely in patient communities as an unexpected bonus.

Downsides people describe most often

• Nausea, sometimes with vomiting (frequently reported). The single most reported side effect, mentioned by roughly a third of reviewers. It tends to peak in the first weeks and after each dose increase, often easing within a week or two, and flares after overeating or fatty food. Many manage it with smaller, lighter meals and plenty of water.
• Sulfur or "egg" burps (commonly reported). Foul-smelling burps compared to rotten eggs or sulfur, often after a dose increase, sometimes with bloating and a sense of food sitting too long. People note they show up far more often than official lists suggest, and often fade with time.
• Bowel changes — constipation and diarrhea (commonly reported), sometimes alternating. Constipation can mean hard, infrequent stools; diarrhea is often worse in the days right after a dose or after rich food.
• Acid reflux and heartburn (occasionally reported), often alongside burping and bloating, tracking with dose increases.
• Fatigue early on (commonly reported), especially the day or two after an injection and in the first weeks, usually easing with time.
• Food aversions, taste changes and over-suppressed appetite (occasionally reported): active aversions to fatty or meaty foods, a metallic taste, a heightened and unpleasant sensitivity to smells, and — for a few — appetite suppression so strong they must remind themselves to eat.
• Headaches and dizziness (occasionally reported), often in the first days of a new dose and frequently linked to not drinking enough water or eating too little.
• Injection-site reactions (sometimes reported): mild redness, itching, a small bump or tenderness, generally minor and short-lived.

Semaglutide side effects: the cited safety record

Below is the safety picture from controlled trials and drug-safety monitoring — distinct from the anecdotes above, and cited.

Stomach and gut intolerance, especially while the dose is being raised. Nausea, vomiting, diarrhea and constipation are the dominant adverse effects in the trials and the leading reason people stop. A pooled analysis of the weight-management program found these events were mostly mild-to-moderate and clustered around the dose-increase period ^[13], and a dedicated safety review reported nausea in roughly one-third of patients ^[5]. This one is mechanism, not bad luck: the slowed stomach emptying that helps you feel full is the same effect that can turn your stomach.

A boxed warning for thyroid C-cell tumors. GLP-1 receptor agonists carry this warning because, in rodents given very high exposures, a type of thyroid tumor appeared. A 2024 review concluded that human data do not establish a clear increase in thyroid cancer from semaglutide, so the signal should be read as unconfirmed in people ^[14] — but a personal or family history of medullary thyroid carcinoma or the genetic syndrome MEN-2 is treated as a reason not to use it ^[5].

Acute pancreatitis (a precaution). Inflammation of the pancreas is a class warning; treatment is conventionally stopped if it is suspected. The dedicated safety review notes that pancreatic-cancer signals remain ones for which firm conclusions cannot yet be drawn given how rare the events are ^[5]. This caution is precautionary, not a proven risk jump.

Gallbladder and biliary disease. The safety review found an increased risk of gallstones, attributed largely to the rate and amount of weight lost rather than a direct drug toxicity — but the increase over placebo is a real trial and monitoring finding ^[5].

Pre-existing diabetic eye disease with rapid sugar correction. In SUSTAIN-6, complications of diabetic retinopathy were significantly more frequent (HR 1.76; 95% CI 1.11-2.78), concentrated in people who already had retinopathy and whose blood sugar dropped quickly ^[2]. The leading explanation is early worsening driven by the speed of correction, not direct eye toxicity; monitoring is advised when sugar is brought down fast ^[5].

Loss of muscle along with fat. A body-composition substudy using DXA scans found the weight lost included both fat and a meaningful share of lean (muscle) mass ^[16]. Because fast, large weight loss can erode muscle, this raises a sarcopenia concern — especially in older adults — and has driven research into protein intake and resistance training. The muscle loss is measured; the downstream risk is a reasoned extrapolation.

Weight regain after stopping. In the STEP 1 extension, people regained a mean of about 11.6 percentage points of body weight within a year of stopping, and the metabolic improvements drifted back toward baseline ^[17]; the STEP 4 withdrawal design showed the same regain after switching to placebo ^[9]. The honest framing: this behaves like a chronic treatment, not a cure.

Pregnancy. Semaglutide is contraindicated in pregnancy. Because the drug lingers — roughly one week half-life, near-complete clearance only about five weeks after the last dose — label guidance is to stop well before a planned pregnancy, commonly cited as about two months ^[20].

Semaglutide hair loss

Hair shedding shows up in user reports and in safety databases, usually noticed a few months in, sometimes alongside a thinner, more hollow face from rapid weight loss. The evidence points away from a direct drug effect. A pharmacovigilance analysis flagged a reporting signal for alopecia (hair loss) with semaglutide and tirzepatide ^[18], and a separate dermatology study tied telogen effluvium — a reversible, diffuse shedding — to the magnitude and speed of weight loss ^[19]. The most consistent read is that this is rapid-weight-loss-associated telogen effluvium, the same temporary shedding that follows any sharp weight drop, rather than the molecule attacking hair follicles. People generally describe it as temporary.

Then and now

Semaglutide is the product of Novo Nordisk's incretin-peptide chemistry, built on the company's earlier GLP-1 analogue and engineered for once-weekly dosing through DPP-4 resistance and fatty-acid acylation. It first reached FDA approval for type 2 diabetes in 2017 ^[3], with an oral once-daily formulation arriving in 2019-2020 and a chronic weight-management indication in 2021 ^[1]. Its cardiovascular-outcomes evidence read out in 2023 ^[3] and its kidney-outcomes evidence in 2024 ^[6], with the corresponding approvals following in 2024-2025; a MASH (a form of inflamed fatty-liver disease) indication came in 2025. During a federally declared shortage from roughly 2022 to early 2025, compounding pharmacies were permitted to produce it; that pathway was curtailed once the shortage was declared resolved in early 2025 ^[2].